The Middle-East and Africa Leukemia Therapeutics market has been estimated at USD 0.45 Billion in 2016 and is projected to reach USD 0.70 Billion by 2021, at a CAGR of 9.23% during the forecast period from 2016 to 2021. Leukemia is a type of cancer where abnormal white blood cells crowd the bone marrow and other organs such as liver, spleen, and kidneys through blood and prevent its normal functions. It is commonly caused due to the high exposure to radiations, unhealthy lifestyle, genetic factors, and environmental conditions. It is common in adults and is observed to progress with aging.
Browse market data tables and in-depth TOC of the Middle-East and Africa Leukemia Therapeutics Market to 2021 @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-leukemia-therapeutics-market-827/
The factor that is driving the market for Leukemia Therapeutics in Middle-east and Africa is simultaneous increase in increasing awareness about cancer treatments and drugs, along with increasing occurrence. Also, due to increasing aging population, the market is driven, as the disease is common with aging. But the market is feared to decline due to high costs of treatment and drugs.
Middle-East and Africa market for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the market is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia. By diagnosis, the market is further sub-segmented into CT scan, biopsy and MRI. By treatments, the market is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy. By drugs, the market is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic market. Gleevec was the one of the major market growth contributors, in the drugs category.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-leukemia-therapeutics-market-827/request-sample
Geographically, Middle-East and Africa market for Leukemia Therapeutics is segmented into Middle-East region and Africa region. Factors such as rising prevalence of Leukemia, growing awareness of cancer screening programs, and rising awareness for healthcare among the population in developing nations of the region are making the companies to penetrate into this market.
F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited , Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc. are the major players of Middle-East and Africa Leukemia Therapeutics market.
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases